Lind Global Fund II LP 13D and 13G filings for Cyclacel Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 7:21 pm Sale | 2024-09-30 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Lind Global Fund II LP | 0 0.000% | -102,250 (Position Closed) | Filing |
| 2024-01-04 4:30 pm Purchase | 2023-12-26 | 13G | Cyclacel Pharmaceuticals, Inc. CYCC | Lind Global Fund II LP | 102,250 9.900% | 102,250 (New Position) | Filing |